ES2648053T3 - Procedimiento de tratamiento de dolor neuropático - Google Patents
Procedimiento de tratamiento de dolor neuropático Download PDFInfo
- Publication number
- ES2648053T3 ES2648053T3 ES10729463.9T ES10729463T ES2648053T3 ES 2648053 T3 ES2648053 T3 ES 2648053T3 ES 10729463 T ES10729463 T ES 10729463T ES 2648053 T3 ES2648053 T3 ES 2648053T3
- Authority
- ES
- Spain
- Prior art keywords
- formulation
- formulations
- water
- weight
- cycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 2
- 208000004296 neuralgia Diseases 0.000 title 1
- 208000021722 neuropathic pain Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract description 43
- 238000009472 formulation Methods 0.000 abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract description 11
- 229960002372 tetracaine Drugs 0.000 abstract description 6
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 abstract description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 5
- 229960004194 lidocaine Drugs 0.000 abstract description 5
- 230000003444 anaesthetic effect Effects 0.000 abstract description 2
- 238000010099 solid forming Methods 0.000 abstract description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 abstract 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 abstract 1
- 229960003150 bupivacaine Drugs 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 239000003589 local anesthetic agent Substances 0.000 abstract 1
- 229960001807 prilocaine Drugs 0.000 abstract 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001549 ropivacaine Drugs 0.000 abstract 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 10
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 8
- YCCRFDDXAVMSLM-UHFFFAOYSA-N 4-(butylamino)benzoic acid Chemical compound CCCCNC1=CC=C(C(O)=O)C=C1 YCCRFDDXAVMSLM-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000001570 sorbitan monopalmitate Substances 0.000 description 5
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 5
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 5
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 4
- 229940038472 dicalcium phosphate Drugs 0.000 description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- 239000003871 white petrolatum Substances 0.000 description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- SMYHRJOQEVSCKS-UHFFFAOYSA-N methyl 4-hydroxybenzoate;propyl 4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1 SMYHRJOQEVSCKS-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulación anestésica local formadora de sólidos que comprende: una anestesia local que comprende lidocaína, tetracaína, prilocaína, ropivacaína o bupivacaína o mezclas de los mismos, en la que la cantidad total de la anestesia local es del 4 % en peso al 15 % en peso en base a la formulación total, del 12 % en peso al 30 % en peso de alcohol de polivinilo y agua caracterizada porque la relación de agua respecto a alcohol de polivinilo es superior a 2,5.
Description
Según la invención como formulaciones reivindicadas 7 y 9 a 11 son ejemplos de referencia. El contenido total de agua de la formulación es significativamente importante desde el punto de vista de estabilidad química y tiempo de secado. Se ha mostrado que en solución acuosa, la tetracaína se hidroliza a ácido 4-butilaminobenzoico (4-BABA) y 5 2-dimetilaminoetanol (DMAE). Por lo tanto, los productos de degradación en la formulación deben minimizarse para asegurar una potencia y pureza óptimas de la formulación. Estudios de diversas formulaciones (véase la tabla a continuación) han demostrado que los niveles de 4-BABA en la formulación tienen correlación con el contenido de agua total en la formulación. En este sentido es deseable mantener los niveles de 4-BABA por debajo del 3 % después de 24 meses de almacenamiento a 5 ºC (vida útil), por ejemplo, sería deseable asegurar que el contenido
10 de agua total permanezca por debajo del ~50 %.
- Formulación
- 7 8 9 10 11
- Contenido de agua
- 29,54% 31,94% 42,82% 48,88% 51,87%
- Nivel de 4-BABA después de 12 meses de almacenamiento a 5 ºC
- 0,75% 0,82% 1,09% 1,42% 1,50%
- Nivel de 4-BABA proyectado después de 24 meses de almacenamiento a 5 ºC
- 1,50% 1,64% 2,18% 2,84% 3,00%
- Ingredientes
- Lidocaína (base) Tetracaína (base) Agua potable Fosfato de DiCalcio Alcohol de polivinilo Vaselina blanca Span 40 (Monopalmitato de sorbitán) Metilparabeno Propilparabeno Almidón de maíz Total
- 7,00% 7,00% 29,54% 32,40% 12,00% 10,00% 2,00% 0,05% 0,01% -100,00% 7,00% 7,00% 31,94% 30,00% 12,00% 10,00% 2,00% 0,05% 0,01% -100,00% 7,00% 7,00% 42,82% -19,77% -3,30% 0,09% 0,02% 20,00% 100,00% 7,00% 7,00% 48,88% -27,00% 8,00% 2,00% 0,10% 0,02% -100,00% 7,00% 7,00% 51,87% -24,00% 8,00% 2,00% 0,10% 0,03% -100,00%
También cabe destacar que el contenido total de agua tiene un impacto directo sobre el tiempo de secado de la formulación. Puesto que la evaporación de agua causa que la formulación forme una capa solidificada, se espera que el contenido total de agua tendrá un impacto directo en el tiempo de secado. Se han estudiado varias formulaciones para evaluar el impacto del contenido de agua sobre el tiempo de secado y los resultados que se
15 proporcionan a continuación indican que una formulación con un 30 % de agua estaba completamente seca al tacto en aproximadamente 10 minutos, mientras que formulaciones con un 40 % y un 54 % de agua requirieron aproximadamente 30 y 60 minutos, respectivamente, para estar secas al tacto. Seco al tacto significa que la superficie de la capa de la formulación está lo suficientemente solidificada de modo que un ligero toque por un dedo no retira ninguna formulación de la capa.
- Formulación
- 12 13 14
- Contenido de agua
- 31,94% 39,94% 54,27%
- Tiempo de secado
- Inferior a 10 minutos Entre 10-30 minutos Entre 30-60 minutos
- Ingredientes
- Lidocaína (base) Tetracaína (base)
- 7,00% 7,00% 7,00% 7,00% 7,00% 7,00%
(continuación)
- Formulación
- 12 13 14
- Agua potable Fosfato de DiCalcio Alcohol de polivinilo Vaselina blanca Span 40 (Monopalmitato de sorbitán) Span 60 (Monoestearato de sorbitán) Metilparabeno
- 31,94% 30,00% 12,00% 10,00% 2,00% -0,05% 39,94% 18,00% 14,00% 10,00% -4,00% 0,05% 54,27% -21,60% 8,00% 2,00% -0,10%
- Formulación
- 12 13 14
- Propilparabeno Total
- 0,01% 100,00% 0,01% 100,00% 0,03% 100,00%
Según la invención como formulaciones reivindicadas 15 y 16 son ejemplos de referencia. Puesto que las formulaciones en el presente documento pueden almacenarse en condiciones refrigeradas, el impacto de 5 temperaturas muy frías, congeladas o de ciclos (congelado-descongelado) sobre las formulaciones pueden considerarse para mejorar la formulación. Los ciclos congelado-descongelado pueden causar que las moléculas de PVA en las formulaciones se reticulen, resultando en un aumento dramático en la viscosidad lo que puede hacer que la formulación sea difícil de extender sobre la piel. Se realizó una serie de estudios (congelado-descongelado) sobre varias formulaciones para evaluar el impacto de la exposición a múltiples ciclos "congelado-descongelado". Un ciclo
10 congelado-descongelado se define como una exposición a condiciones de congelado (es decir, -20 ºC) durante 2-3 días seguido por la exposición a condiciones de descongelado (es decir, 25 ºC) durante 2-3 días. Una formulación más robusta mostrará un aumento inferior en la viscosidad después de su exposición a múltiples ciclos congeladodescongelado.
Se han desarrollado varias formulaciones y se han sometido a ciclos de congelado-descongelado. La viscosidad en
15 el valor basal y después de cada ciclo congelado-descongelado se midió usando el procedimiento que se describe en el ejemplo 5.
Los datos reunidos en las formulaciones a continuación indican que el agua respecto a la relación PVA tiene un impacto sobre la resistencia a exposiciones de congelado/descongelado. Las formulaciones que tenían una relación agua/PVA superior a 2,5 mostraron aumentos en la viscosidad menos pronunciados después de su exposición a
20 múltiples ciclos de congelado/descongelado, tomo se muestra en la tabla a continuación.
- Formulación
- 15 16 17 18 19
- Relación agua/PVA
- 2,16 2,46 2,57 2,85 3,16
- Ingredientes
- Lidocaína (base) Tetracaína (base) Agua potable Fosfato de DiCalcio Alcohol de polivinilo Vaselina blanca Span 40 (Monopalmitato de sorbitán)
- 7,00% 7,00% 25,94% 36,00% 12,00% 10,00% 2,00% 7,00% 7,00% 29,54% 32,40% 12,00% 10,00% 2,00% 7,00% 7,00% 35,94% 27,00% 14,00% 5,00% - 7,00% 7,00% 39,94% 18,00% 14,00% 10,00% - 7,00% 7,00% 37,94% 24,00% 12,00% 10,00% 2,00%
(continuación)
- Formulación
- 15 16 17 18 19
- Span 60 (Monoestearato de sorbitán)
- - - 4,00% 4,00% -
- Metilparabeno
- 0,05% 0,05% 0,05% 0,05% 0,05%
- Propilparabeno
- 0,01% 0,01% 0,01% 0,01% 0,01%
- Total
- 100,00% 100,00% 100,00% 100,00% 100,00%
- Viscosidad inicial
- 454.500 146.000 122.500 79.500 47.800
- Resultados de viscosidad de congelado/descongelado
- 1 ciclo 7.200.000
- 436.500 170.000 94.500 29.440
- 2 ciclos >8.000.000
- 427.000 226.500 114.000 29.160
- 3 ciclos >8.000.000
- 1.150.000 210.000 146.000 33.080
- 4 ciclos >8.000.000
- 2.385.000 227.500 87.000 46.400
- 5 ciclos >8.000.000
- 3.310.000 333.000 137.500 38.000
- Múltiple aumento de viscosidad de congelado/descongelado
- 1 ciclo 16
- 3 1 1 1
- 2 ciclos >18
- 3 2 1 1
- 3 ciclos >18
- 8 2 2 1
- 4 ciclos >18
- 16 2 1 1
- 5 ciclos >18
- 23 3 2 1
Se fabricaron dos formulaciones anestésicas locales formadoras de sólidos y sus composiciones se enumeran en la siguiente tabla. Las formulaciones son idénticas excepto que la formulación 20 usó Span 40 (Monopalmitato de sorbitán) como agente emulsionante y la formulación 21 usó Span 60 (Monoestearato de (sorbitán). Después de aproximadamente tres meses, la formulación 20 mostró significativamente más separación de fase que la formulación 21.
- Formulación
- 20 21
- Ingredientes
- Lidocaína Tetracaína Agua potable Fosfato de DiCalcio Alcohol de polivinilo Vaselina blanca Span 40 (Monopalmitato de sorbitán) Span 60 (Monoestearato de (sorbitán)
- 7,00% 7,00% 35,94% 27,00% 14,00% 5,00% 4,00% - 7,00% 7,00% 35,94% 27,00% 14,00% 5,00% -4,00%
(continuación)
- Formulación
- 20 21
- Ingredientes
- Metilparabeno Propilparabeno Total
- 0,05% 0,01% 100,00% 0,05% 0,01% 100,00%
- Viscosidad inicial
- 132.000 122.500
- Relación agua/PVA
- 2,57 2,57
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14266209P | 2009-01-06 | 2009-01-06 | |
| US142662P | 2009-01-06 | ||
| PCT/US2010/020255 WO2010080831A1 (en) | 2009-01-06 | 2010-01-06 | Method of treating neuropathic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2648053T3 true ES2648053T3 (es) | 2017-12-28 |
Family
ID=42316788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10729463.9T Active ES2648053T3 (es) | 2009-01-06 | 2010-01-06 | Procedimiento de tratamiento de dolor neuropático |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9012477B2 (es) |
| EP (1) | EP2378873B1 (es) |
| JP (3) | JP6015890B2 (es) |
| CN (2) | CN104257647B (es) |
| AU (1) | AU2010203710B2 (es) |
| CA (1) | CA2749084C (es) |
| ES (1) | ES2648053T3 (es) |
| PL (1) | PL2378873T3 (es) |
| RU (1) | RU2554494C2 (es) |
| WO (1) | WO2010080831A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012477B2 (en) | 2009-01-06 | 2015-04-21 | Nuvo Research Inc. | Method of treating neuropathic pain |
| WO2010085589A2 (en) | 2009-01-22 | 2010-07-29 | G&H Brands Llc | Desensitizing drug product |
| US20110086913A1 (en) * | 2009-04-01 | 2011-04-14 | Jie Zhang | Methods for treating myofascial, muscle, and/or back pain |
| WO2010129542A1 (en) * | 2009-05-04 | 2010-11-11 | Jie Zhang | Methods of treating pains associated with neuroma, nerve entrapment, and other conditions |
| US9186334B2 (en) | 2009-05-04 | 2015-11-17 | Nuvo Research Inc. | Heat assisted lidocaine and tetracaine for transdermal analgesia |
| MX2012008168A (es) * | 2010-01-14 | 2013-02-07 | Nuvo Res Inc | Formulaciones anestesicas locales que forman solidos para control del dolor. |
| US9962391B2 (en) | 2011-12-27 | 2018-05-08 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| US11213501B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| US9468599B2 (en) | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| US11213500B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| US10813897B2 (en) | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| CN111840553A (zh) * | 2019-04-15 | 2020-10-30 | 湖州依诺唯新药物制剂有限公司 | 脂性药物制剂及其应用 |
| EP4225289A1 (en) * | 2020-11-21 | 2023-08-16 | Cellix Bio Private Limited | Pharmaceutical compositions for use in the management and treatment of pain |
| CN115068411A (zh) * | 2022-06-29 | 2022-09-20 | 上海洛清医药科技有限公司 | 利多卡因-丁卡因复方乳膏及其制备方法 |
| CN116098882A (zh) * | 2023-04-06 | 2023-05-12 | 山东诚创蓝海医药科技有限公司 | 一种含利多卡因丙胺卡因的组合物及其制备方法 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929131A (en) | 1975-01-09 | 1975-12-30 | Thomas L Hardwick | Bandage and method of using same |
| JPS5279018A (en) | 1975-12-24 | 1977-07-02 | Kuraray Co Ltd | Analgesic embrocation |
| SE432192B (sv) | 1977-12-01 | 1984-03-26 | Astra Laekemedel Ab | En lokalanestetisk emulsionsalva for utvertes bruk av typen olja-i-vatten-emulsion |
| SE7713618L (sv) | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | Lokalanestetisk blandning |
| US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
| US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
| JPS60174716A (ja) | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
| US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
| CA1248450A (en) | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
| GB2163959A (en) | 1984-08-08 | 1986-03-12 | Craig Med Prod Ltd | Ostomy appliance |
| US4747841A (en) | 1985-03-19 | 1988-05-31 | Yasuro Kuratomi | Methods and instruments of moxibustion |
| JPS6251617A (ja) | 1985-08-30 | 1987-03-06 | Wako Pure Chem Ind Ltd | ビダラビンゲル軟膏 |
| US4780320A (en) | 1986-04-29 | 1988-10-25 | Pharmetrix Corp. | Controlled release drug delivery system for the periodontal pocket |
| US4693706A (en) | 1986-08-11 | 1987-09-15 | Mark L. Anderson | Two compartment mixing syringe |
| EP0258521B1 (de) | 1986-08-23 | 1990-05-02 | Arno Walter Latzke | Mittel zur Applikation von transdermal resorbierbaren Wirkstoffen |
| US4911707A (en) | 1987-02-13 | 1990-03-27 | Ciba-Geigy Corporation | Monolithic user-activated transdermal therapeutic system |
| GB8712518D0 (en) | 1987-05-28 | 1987-07-01 | Univ Belfast | Unit-dose film composition |
| DK158336C (da) | 1987-09-22 | 1990-10-01 | Coloplast As | Forbindsmateriale til behandling af saar samt smaalegemer til brug ved fremstilling deraf |
| US4830855A (en) | 1987-11-13 | 1989-05-16 | Landec Labs, Inc. | Temperature-controlled active agent dispenser |
| JPH01122037U (es) | 1988-02-12 | 1989-08-18 | ||
| DE3806562A1 (de) | 1988-03-01 | 1989-09-14 | Alpha Therapeutic Gmbh | Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff |
| US4913957A (en) | 1988-05-23 | 1990-04-03 | Kimberly-Clark Corporation | Thermal retaining fabric laminate |
| US5378730A (en) | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
| DE3903794A1 (de) | 1989-02-09 | 1990-08-16 | Lohmann Therapie Syst Lts | Therapeutisches system zur transdermalen oder transmucosalen verabreichung von wirkstoffen und seine verwendung |
| EP0386960A3 (en) | 1989-03-07 | 1991-10-23 | American Cyanamid Company | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
| US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US5276032A (en) | 1989-12-28 | 1994-01-04 | King O Newton | Vision aid and anesthetic composition |
| US5229133A (en) | 1990-01-24 | 1993-07-20 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| CA2040460C (en) | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Drug delivery with thermoreversible gels |
| US5279594A (en) | 1990-05-23 | 1994-01-18 | Jackson Richard R | Intubation devices with local anesthetic effect for medical use |
| US5114411A (en) | 1990-11-19 | 1992-05-19 | Habley Medical Technology Corporation | Multi-chamber vial |
| US5108710A (en) | 1990-11-26 | 1992-04-28 | Little Amy C | Transdermal patch holder |
| EP0569532A1 (en) | 1991-02-01 | 1993-11-18 | Stiefel Laboratories, Inc. | Improved flexible collodion compositions |
| US5213129A (en) | 1991-03-25 | 1993-05-25 | Csb Limited Partnership | Fluid mixing device |
| US5329976A (en) | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
| US5330452A (en) | 1993-06-01 | 1994-07-19 | Zook Gerald P | Topical medicating device |
| DK0752898T3 (da) | 1994-03-30 | 1999-02-15 | Alza Corp | Mindskning af hudirritation ved elektrotransport-tilførsel |
| SE9404438D0 (sv) | 1994-12-21 | 1994-12-21 | Astra Ab | New process |
| DE19526031A1 (de) | 1995-07-17 | 1997-01-23 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Rückenschmerz und Muskelverspannung |
| DE19526019A1 (de) | 1995-07-17 | 1997-01-23 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Kopfschmerzen |
| US6756053B2 (en) | 1995-07-28 | 2004-06-29 | Zars, Inc. | Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
| US5658583A (en) | 1995-07-28 | 1997-08-19 | Zhang; Jie | Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| AR004691A1 (es) | 1995-10-27 | 1999-03-10 | Astrazeneca Ab | Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion |
| ES2138130T3 (es) | 1995-10-28 | 2000-01-01 | Braun Melsungen Ag | Composicion farmaceutica que contiene un anestesico local y/o un analgesico de accion central. |
| US5906814A (en) | 1995-12-07 | 1999-05-25 | The Andrew Jergens Company | Topical film-forming compositions |
| SE9601421D0 (sv) | 1996-04-12 | 1996-04-12 | Astra Ab | New composition |
| AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
| US20030008396A1 (en) | 1999-03-17 | 2003-01-09 | Ku David N. | Poly(vinyl alcohol) hydrogel |
| US5885597A (en) | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
| SE9704031D0 (sv) | 1997-11-05 | 1997-11-05 | Astra Ab | Novel formulation |
| US6036966A (en) | 1998-02-17 | 2000-03-14 | Youssefyeh; Rena T. | Skin treatment compositions comprising protein and enzyme extracts |
| US5993836A (en) | 1998-04-28 | 1999-11-30 | Castillo; James G. | Topical anesthetic formulation |
| US6955819B2 (en) | 1998-09-29 | 2005-10-18 | Zars, Inc. | Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances |
| EP1117357B1 (en) | 1998-09-29 | 2013-06-26 | Nuvo Research Inc. | Apparatus for improved administration of pharmaceutically active compounds |
| US7063859B1 (en) | 1999-04-28 | 2006-06-20 | Noven Pharmaceuticals, Inc. | Barrier film lined backing layer composition and method for topical administration of active agents |
| US6453648B1 (en) | 1999-07-06 | 2002-09-24 | Zars, Inc. | Method for manufacturing a heat generating apparatus |
| AU6076200A (en) | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
| US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| RU2201219C2 (ru) * | 2001-04-24 | 2003-03-27 | Макаров Константин Алексеевич | Фармакологическая композиция пролонгированного действия |
| US20030124174A1 (en) | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
| US6756426B2 (en) | 2001-12-20 | 2004-06-29 | I-Tek, Inc. | Lightweight composite material for protective pads, cushions, supports or the like and method |
| EP1517709B1 (en) | 2002-06-20 | 2008-06-11 | Amnon Sintov | Transdermal drug delivery system |
| CN100438869C (zh) | 2002-07-29 | 2008-12-03 | 兴和株式会社 | 吲哚美辛外用剂 |
| CA2536482C (en) | 2003-08-25 | 2012-07-24 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US20070059351A1 (en) | 2003-10-17 | 2007-03-15 | Murrell George A C | Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods |
| US20050209319A1 (en) | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| WO2005110275A1 (en) | 2004-05-07 | 2005-11-24 | Phytotox Limited | Methods of treating wounds with gonyautoxins |
| US20070189978A1 (en) | 2004-06-07 | 2007-08-16 | Jie Zhang | Compositions and methods for dermally treating musculoskeletal pain |
| US20070196323A1 (en) | 2004-06-07 | 2007-08-23 | Jie Zhang | Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs |
| US8741332B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
| US8907153B2 (en) * | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
| US7878187B2 (en) | 2005-09-23 | 2011-02-01 | Wyeth Llc | Heat cells comprising exothermic compositions having absorbent gelling material |
| JP2009524586A (ja) | 2005-12-14 | 2009-07-02 | ザーズ， インコーポレイテッド | 疼痛を皮膚処置するための組成物および方法 |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| WO2008150995A2 (en) | 2007-06-01 | 2008-12-11 | Zars Pharma, Inc. | Transdermal drug delivery systems for delivering anti-inflammatory drugs |
| FR2921905B1 (fr) | 2007-10-04 | 2012-09-28 | Sartorius Stedim Biotech | Recipient de traitement et/ou de controle de produits comprenant une chambre de protection de moyens de traitement et/ou de controle de ces produits, et conteneur comprenant un tel recipient |
| EP2163956A1 (de) | 2008-09-10 | 2010-03-17 | Siemens Aktiengesellschaft | Verfahren zur Bereitstellung einer Steuerungsinformation für eine verteilte Operation in einem Automatisierungssystem, Computerprogramm und Automatisierungssystem |
| US9012477B2 (en) | 2009-01-06 | 2015-04-21 | Nuvo Research Inc. | Method of treating neuropathic pain |
| US20110086913A1 (en) | 2009-04-01 | 2011-04-14 | Jie Zhang | Methods for treating myofascial, muscle, and/or back pain |
| WO2010129542A1 (en) | 2009-05-04 | 2010-11-11 | Jie Zhang | Methods of treating pains associated with neuroma, nerve entrapment, and other conditions |
| MX2012008168A (es) | 2010-01-14 | 2013-02-07 | Nuvo Res Inc | Formulaciones anestesicas locales que forman solidos para control del dolor. |
-
2010
- 2010-01-05 US US12/652,502 patent/US9012477B2/en active Active
- 2010-01-06 WO PCT/US2010/020255 patent/WO2010080831A1/en not_active Ceased
- 2010-01-06 PL PL10729463T patent/PL2378873T3/pl unknown
- 2010-01-06 RU RU2011133036/15A patent/RU2554494C2/ru active
- 2010-01-06 CN CN201410453042.0A patent/CN104257647B/zh active Active
- 2010-01-06 EP EP10729463.9A patent/EP2378873B1/en active Active
- 2010-01-06 AU AU2010203710A patent/AU2010203710B2/en not_active Ceased
- 2010-01-06 CN CN201080008641.1A patent/CN102325447B/zh active Active
- 2010-01-06 CA CA2749084A patent/CA2749084C/en active Active
- 2010-01-06 ES ES10729463.9T patent/ES2648053T3/es active Active
- 2010-01-06 JP JP2011544676A patent/JP6015890B2/ja active Active
-
2014
- 2014-10-06 JP JP2014205424A patent/JP6144659B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-12 JP JP2016024580A patent/JP6161744B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010203710B2 (en) | 2013-10-10 |
| US9012477B2 (en) | 2015-04-21 |
| JP2012514603A (ja) | 2012-06-28 |
| JP2016084368A (ja) | 2016-05-19 |
| JP6144659B2 (ja) | 2017-06-07 |
| EP2378873A1 (en) | 2011-10-26 |
| CN104257647A (zh) | 2015-01-07 |
| JP2015003927A (ja) | 2015-01-08 |
| CN102325447A (zh) | 2012-01-18 |
| CN104257647B (zh) | 2017-10-27 |
| US20110015229A1 (en) | 2011-01-20 |
| JP6015890B2 (ja) | 2016-10-26 |
| EP2378873A4 (en) | 2012-06-20 |
| CA2749084C (en) | 2017-03-14 |
| JP6161744B2 (ja) | 2017-07-12 |
| PL2378873T3 (pl) | 2018-03-30 |
| RU2554494C2 (ru) | 2015-06-27 |
| EP2378873B1 (en) | 2017-08-23 |
| CA2749084A1 (en) | 2010-07-15 |
| AU2010203710A1 (en) | 2011-07-28 |
| CN102325447B (zh) | 2014-09-24 |
| WO2010080831A1 (en) | 2010-07-15 |
| HK1166237A1 (en) | 2012-10-26 |
| RU2011133036A (ru) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2369719T3 (es) | Composiciones fumigantes azeotrópicas de yoduro de metilo. | |
| AU2010246847B2 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
| JP2012528830A5 (es) | ||
| BR112015000088B1 (pt) | composições farmacêuticas compreendendo rifamixinaa e aminoácidos, método de preparação e uso das mesmas | |
| CN102325447A (zh) | 治疗神经病性痛的方法 | |
| ES2200467T3 (es) | Concentrado desinfectante y esterilizante que contiene un dialdehido aromatico y un sistema de tamponamiento de ph neutro. | |
| Stringa et al. | Defining the nonreturn time for intestinal ischemia reperfusion injury in mice | |
| MX363417B (es) | Composicion vaginal a base de poliglucosidos de alquilo. | |
| PT1635852E (pt) | ''utilização de composições para reconstituição de unhas para aplicação tópica em onicosquise'' | |
| Omar et al. | A study of the cardioprotective effect of spermidine: A novel inducer of autophagy | |
| AU2013342069B2 (en) | Enema composition for treatment of ulcerative colitis having long term stability | |
| BR112020007102B1 (pt) | Concentrado líquido para preservação | |
| ES2375784B1 (es) | Gel de ácido tranexámico | |
| US20240299618A1 (en) | Means and methods for wound healing | |
| CN113261559A (zh) | 一种低温季铵盐消毒液及其制备方法 | |
| ES2915824T3 (es) | Composición farmacéutica antiviral de uso tópico | |
| Holt | Substances which inhibit ice nucleation: a review | |
| EP1637141B1 (en) | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | |
| KR20150030525A (ko) | 구제역바이러스 소독용 조성물 | |
| ME02578B (me) | Veterinarska kompozicija za dermalnu primenu | |
| CA2621059C (en) | Stabilized protease composition | |
| FR3046794B1 (fr) | Nouvelle composition cryogenique | |
| Kang MiYoung et al. | Efficacy test of commercially available disinfectants against foot-and-mouth virus under subzero temperature using anti-freezing diluents. | |
| CN115486448A (zh) | 一种灭活SARS-CoV-2病毒的-80摄氏度低温消毒液 | |
| Milton et al. | The effects of the protein synthesis inhibitor anisomycin on the febrile responses to intracerebroventricular injections of bacterial pyrogen, arachidonic acid and prostaglandin E2 |